Article
K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.
PloS one - 1 Jan 2012
Hofmann Irmgard, Weiss Andreas, Elain Gaelle, Schwaederle Maria, Sterker Dario, Romanet Vincent, Schmelzle Tobias, Lai Albert, Brachmann Saskia M, Bentires-Alj Mohamed, Roberts Thomas M, Sellers William R, Hofmann Francesco, Maira Sauveur-Michel
Abstract excerpt
Activating K-RAS mutations occur at a frequency of 90% in pancreatic cancer, and to date no therapies exist targeting this oncogene. K-RAS signals via downstream effector pathways such as the MAPK and the PI3K signaling pathways, and much effort has been focused on developing drugs targeting comp...
Topics
- Animals
- Benzimidazoles
- Cell Line, Tumor
- Cell Proliferation
- Extracellular Signal-Regulated MAP Kinases
- Female
- Gene Knockdown Techniques
- HEK293 Cells
- Humans
- Indazoles
- Mice
- Mice, Nude
- Mitogen-Activated Protein Kinase Kinases